Lucius Sotorasib – Buy online
Sotorazib is a prescription drug that targets the KRAS G12C mutant protein. It received accelerated approval from the U.S. FDA on May 28, 2021. Patients should use it only as directed by their doctor.
View Product
NEJM: Sotorasibi combined with panitumumab may prolong progression-free survival in patients with KRAS G12C-mutant refractory colorectal cancer – MedSci
NEJM：治疗KRAS G12C突变的难治性结直肠癌患者，索托拉西布联合帕尼单抗或可延长无进展生存期 梅斯医学 MedSci
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Products Mentioned in This Article
These products were automatically matched from the article title, summary, and full content.
SOTOLDX Sotorasib 120mg
On May 29, 2021, the U.S. FDA announced accelerated approval for sotorasib (AMG510) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring KRAS G12C mutations. These patients had received at least one prior systemic therapy. This is the world's first anticancer therapy targeting a specific KRAS gene mutation.
View Product
Frequently Asked Questions
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Sotorasib – Buy online、SOTOLDX Sotorasib 120mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
